A5009766564- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Effects of Radiation Exposure
- Ferroptosis and cancer prognosis
- Radiopharmaceutical Chemistry and Applications
- Advanced Radiotherapy Techniques
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Renal and related cancers
- Cancer Diagnosis and Treatment
- Radiation Effects and Dosimetry
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Fibroblast Growth Factor Research
- Genital Health and Disease
- Esophageal Cancer Research and Treatment
- Healthcare Systems and Public Health
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
Ministry of Health of the Russian Federation
2014-2024
Medical Radiological Research Center
2014-2024
Academy of Medical Sciences
2020
Abstract Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell carcinoma (RCC). Experimental Design: In a randomized, open-label, multicenter, phase II/III study, 513 patients with RCC received Nap (15 μg/kg i. v. three cycles four once-daily injections) (9 MU s.c. times weekly), or same regimen monotherapy. The primary endpoint was overall survival (OS). Results: This study did not meet its endpoint. Median OS/PFS for...
13 Background: Docetaxel/prednisone is standard first-line chemotherapy for mCRPC. Aflibercept (known as ziv-aflibercept in the US) a recombinant human fusion protein that binds VEGF-A, VEGF-B and Placental Growth Factor (PlGF), thereby inhibiting angiogenesis. Methods: VENICE was double-blind, randomized phase III study with overall survival (OS) primary endpoint. Men mCRPC, ECOG PS 0-2, adequate organ function no prior cytotoxic therapy were treated docetaxel (75 mg/m² iv q3w) oral...
INTRODUCTION: The results of studies clinical potential a new domestic radiopharmaceutical 177 Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented this article. OBJECTIVE: pharmacokinetics, safety and tolerability were studied. Tolerability increasing activities — 5.0, 7.5 10.0 GBq was investigated. MATERIALS AND METHODS: study included 12 cancer, who progressed after previous treatment. first 4 treated by 5 Lu DOTA-PSMA, the next second group GBq,...
Background. The proportion of renal cell carcinoma (RCC) in the structure oncological incidence Russia is 3.9 %. This nosology has a leading position by growth rate. number new cases RCC from 2004 to 2014 increased 42.9 Carbonic anhydrase (CA) enzymes are transmembrane that play an important role pH regulation catalyzing reversible reactions carbonic acid carbon dioxide and water. Recently we have seen studies on prognostic predictive value CA9 expression clear RCC. Objective – reveal...
TPS4692^ Background: The phase III TROPIC study (NCT00417079) reported a significant improvement in overall survival (OS) for cabazitaxel (Cbz) + prednisone (P;CbzP) (25 mg/m 2 IV Q3W/10 mg PO QD) vs mitoxantrone (M) P (MP) (median OS 15.1 12.7 mos; HR 0.70; < 0.0001) pts with mCRPC (also known as hormone-refractory prostate cancer) previously treated D-containing regimen. CbzP is approved by the FDA, EMA and other health authorities treatment of that has progressed after Cbz toxicity...
5002 Background: Docetaxel/prednisone is standard first-line chemotherapy for men with mCRPC. Aflibercept a recombinant human fusion protein that binds A and B isoforms of Vascular Endothelial Growth Factor Placental-derived Factors, thereby inhibiting angiogenesis. Methods: We performed an international double-blind randomized trial (known as VENICE) which recruited mCRPC, adequate organ function no prior chemotherapy. Men were treated docetaxel (75mg/m² intravenously every 3 weeks) oral...
Bladder cancer is the 9th most common malignant tumor worldwide. Muscle-invasive bladder an aggressive neoplasm with a tendency for early metastases. The main approach muscle-invasive treatment radical cystectomy lymph node dissection and polychemotherapy. In recent decades, organ-preserving conservative therapy has been actively investigated. Currently, studied to of trimodality which includes transurethral resection wall tumor, chemotherapy, external beam radiotherapy. article presents...
Background. Among malignant tumors in men Russia, prostate cancer is the most common comprising 17 %. Despite high effectiveness of radiotherapy for about 20 % patients, radiation damage pelvic organs develops affecting bladder, rectum, and intrapelvic cellular tissue. Aim. To evaluate early late complications dose-rate brachytherapy. Materials methods. Literature review was performed, our own results treatment 276 patients using brachytherapy as monotherapy with different fractionation...
Renal cell carcinoma (RCC) occupies the 10th place in structure of incidence malignant neoplasms and terms growth is second only to prostate cancer. The RCC reaches a maximum by age 70. Men suffer from this pathology twice as often women. In mortality Russian population oncological diseases, among men 2.7%, women – 2.1%. Today surgical approach treatment remains one most effective methods. A detailed knowledge norms, variants anomalies vessels abdominal retroperitoneal space fundamental...
Renal cell carcinoma is one of the most common malignant neoplasms genitourinary system. Disease progression occurs in 30% patients after radical surgical treatment. with metastatic spread to contralateral kidney quite rare (in 1–2% cases). In such cases, differential diagnostics disease primary multiple kidneys relevant. This necessary determine correct treatment for patients.
This review presents the main lines of research on bladder cancer in 2021 and 2022. The largely focuses molecular studies context primary diagnosis disease progression. Based genetic data, 3 types with varying sensitivity to chemotherapy drugs can be identified. treatment approach invasive is cystectomy. Data complications after radical cystectomy different followup periods depending experience, as well comparative results open robot-assisted surgeries time expenditure are discussed. Methods...
Background . Prostate cancer (PCa) is one of the most common malignant diseases in men worldwide, with over 1.1 million cases PCa reported annually. In Russian Federation, proportion patients stage I—II from 2008 to 2018 increased 37.6 % 56 %, which turn allows more and perform radical treatment methods. However, it should be noted that number both recurrent after radiation therapy (external beam (EBRT) or brachytherapy) local recurrence prostatectomy (RPE) steadily increasing. Objective...
This article aims to give an up-to-date review of studies on the diagnosis and treatment patients with bladder cancer (BCa). We emphasize that assessment prognosis using specific markers is a promising method. However, clinical data currently outpace results molecular testing. Patients luminal BCa demonstrate worse response pharmacotherapy than those other types. The implementation new drugs such as avelumab, enfortumab, drug combinations into practice raised hopes improve outcomes locally...
Background. In Russia in 2018, prostate cancer 40.4 % of patients was detected stages III–IV, which requires combined and complex treatment, including hormone therapy. the course tumor inevitably acquires features castration resistance. Currently, there are several drugs for treatment metastatic castration-resistant (mCRPC), however, still no standards optimal drug choice with mCRPC, data on adverse events, duration quality life patients. The study objective is describe regimens mCRPC who...
The paper reviews the basic avenues of research and recent developments in clinical research. Bladder cancer remains a mystery disease, it puts oncologists urologists lot questions that hard to answer. According epidemiological data 2017 bladder incidence increased Russia, late stages was diagnosed large amount patients 2017: 12.9 % all with newly detected stage III diagnosed, 9.9 IV diagnosed. mortality among 14.9 1st year after disease diagnosis. Cancer carried out last decades focused on...
Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate cancer and skeletal metastases were positioned as means suppress pain, reduce analgesics consumption improve the quality of life. They usually administered once in case progressive pain syndrome. Radium chloride [223Ra] is registered multiple metastases, but without visceral metastases. The ALSYMPCA study showed a significantly increased overall survival group receiving radium compared placebo....
Over the last decade there have been significant changes in approaches to drug treatment of renal cell carcinoma. In clinical practice, was a group targeted drugs, purpose which has increased life expectancy patients with advanced kidney cancer. The studies devoted study sequence destination agents, combinations, new drugs and identify prognostic factors, are held.